Veradermics' oral VDPHL01 shows first efficacy data in women, boosting hair count 22.7 hairs/cm² at 6 months; Phase 2/3 trial due 2027.
Veradermics is for the first time reporting positive efficacy of its oral formulation of minoxidil in female pattern hair loss, which broadens the market potential …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Veradermics keeps ‘momentum going’ as baldness drug helps women with hair loss
Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss
Why Hollywood’s Follicle-Challenged Stars Are Harvesting Their Hair
New Peer-Reviewed Study Published in Dermatology and Therapy Adds to Clinical Evidence Showing Nutrafol Hair Growth Nutraceuticals Improve Hair Growth in Women
Q32 bounces back to claim study success for alopecia drug
Novo Nordisk's denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026
The Phase 2 data exceeded expectations, lifting company shares as high as nearly $130 apiece and building the case for what may…
Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with…
Hair Restoration Institute of Minnesota Reports Strong Early Patient Response to Dutasteride Mesotherapy
That miracle pill you’ve read about? Two years out. Banking what you have for future cloning could be the solution you seek.
Un medicamento experimental contra la calvicie mostró mejoras de hasta 86% en pacientes durante un estudio de fase 3. El…
Resultados apontam melhora de até 86% dos pacientes, segundo novo estudo
